Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?

Buryachkovskaya, Liudmila; Lomakin, Nikita; Melkumyants, Arthur; Docenko, Julia; Serebruany, Victor

Buryachkovskaya, Liudmila; Lomakin, Nikita; Melkumyants, Arthur; Docenko, Julia; Serebruany, Victor.

Buryachkovskaya L; National Medical Research Center of Cardiology, Moscow, Russia.
Lomakin N; Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia.
Melkumyants A; National Medical Research Center of Cardiology, Moscow, Russia.
Docenko J; Institute of Physics and Technology, Moscow, Russia.
Serebruany V; National Medical Research Center of Cardiology, Moscow, Russia.

Eur Heart J Cardiovasc Pharmacother ; 7(5): e81-e82, 2021 09 21.

Article in English | MEDLINE | ID: covidwho-1286562

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Blood Cells/drug effects; COVID-19 Drug Treatment; Receptors, Interleukin-6/antagonists & inhibitors; SARS-CoV-2; Antibodies, Monoclonal, Humanized/pharmacology; COVID-19/blood; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Cells / Receptors, Interleukin-6 / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Eur Heart J Cardiovasc Pharmacother Year: 2021 Document Type: Article Affiliation country: Ehjcvp

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google